INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August

Key Points

• INmune Bio's short interest dropped by 29.8% in August, totaling 3,740,000 shares, with 21.9% of the company's stock currently short sold.
• The company's stock has a consensus rating of "Moderate Buy" with an average price target of $18.40, although recent ratings have included downgrades to "sell" from several analysts.
• After reporting an EPS of ($0.34) for the last quarter, INmune Bio is projected to post -2.24 EPS for the current year.

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) saw a significant decline in short interest in August. As of August 31st, there was short interest totaling 3,740,000 shares, a decline of 29.8% from the August 15th total of 5,330,000 shares. Currently, 21.9% of the company's stock are short sold. Based on an average daily volume of 3,410,000 shares, the short-interest ratio is presently 1.1 days. Based on an average daily volume of 3,410,000 shares, the short-interest ratio is presently 1.1 days. Currently, 21.9% of the company's stock are short sold.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Scotiabank reiterated a "sector underperform" rating on shares of INmune Bio in a report on Tuesday, July 1st. BTIG Research reaffirmed a "neutral" rating on shares of INmune Bio in a research note on Tuesday, July 1st. Wall Street Zen lowered shares of INmune Bio from a "hold" rating to a "sell" rating in a research report on Saturday, August 2nd. Maxim Group decreased their target price on shares of INmune Bio from $30.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, July 2nd. Finally, Raymond James Financial lowered shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a research note on Monday, June 30th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.40.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INMB. Geode Capital Management LLC raised its stake in INmune Bio by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 389,931 shares of the company's stock valued at $901,000 after acquiring an additional 25,069 shares during the period. Millennium Management LLC increased its holdings in shares of INmune Bio by 43.9% in the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company's stock valued at $1,360,000 after purchasing an additional 88,823 shares during the last quarter. XTX Topco Ltd raised its position in shares of INmune Bio by 240.9% in the second quarter. XTX Topco Ltd now owns 125,847 shares of the company's stock valued at $291,000 after purchasing an additional 88,928 shares during the period. MAI Capital Management lifted its stake in shares of INmune Bio by 6.0% during the 1st quarter. MAI Capital Management now owns 106,797 shares of the company's stock worth $834,000 after buying an additional 6,030 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of INmune Bio by 9.5% during the 4th quarter. Northern Trust Corp now owns 105,961 shares of the company's stock worth $495,000 after buying an additional 9,154 shares during the period. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Price Performance

INmune Bio stock opened at $1.97 on Tuesday. The company's 50-day moving average is $2.35 and its 200-day moving average is $5.52. The firm has a market capitalization of $52.37 million, a PE ratio of -0.79 and a beta of 1.03. INmune Bio has a fifty-two week low of $1.71 and a fifty-two week high of $11.64.

INmune Bio (NASDAQ:INMB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.03. As a group, analysts expect that INmune Bio will post -2.24 EPS for the current year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.